Figure 1From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study Kaplan-Meier survival analysis of progression-free survival (PFS, dashed dark line) and overall survival (OS, solid dark line) from the start of FOLFOX second-line chemotherapy. Back to article page